However, the degree of inhibition was lower than for most MDS or AML patient samples at the same drug doses, and all myeloid colony subtypes were still present at every dose combination (Figure 9H), suggesting that AML or high-risk MDS cells are more sensitive to this drug combination than healthy human bone marrow CD34+ cells. This evidence concerns the gene CD34 and acute myeloid leukemia.